NASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis $35.25 +0.11 (+0.31%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$35.75 +0.50 (+1.42%) As of 08/7/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cytokinetics Stock (NASDAQ:CYTK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cytokinetics alerts:Sign Up Key Stats Today's Range$34.67▼$35.5950-Day Range$30.88▼$38.8952-Week Range$29.31▼$59.39Volume1.04 million shsAverage Volume1.26 million shsMarket Capitalization$4.21 billionP/E RatioN/ADividend YieldN/APrice Target$70.92Consensus RatingModerate Buy Company Overview Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Read More Cytokinetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreCYTK MarketRank™: Cytokinetics scored higher than 82% of companies evaluated by MarketBeat, and ranked 165th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cytokinetics are expected to decrease in the coming year, from ($5.24) to ($5.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.64% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Cytokinetics has recently increased by 6.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.83 Percentage of Shares Shorted13.64% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Cytokinetics has recently increased by 6.06%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.58 News SentimentCytokinetics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Cytokinetics this week, compared to 10 articles on an average week.Search InterestOnly 3 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows6 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,350,617.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Cytokinetics is held by insiders.Read more about Cytokinetics' insider trading history. Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTK Stock News HeadlinesCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 5,000 SharesJuly 16, 2025 | insidertrades.comCytokinetics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7 at 4:00 PM | globenewswire.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK)August 6 at 2:13 PM | gurufocus.comCytokinetics to Present New Aficamten Data at ESC Congress 2025August 1, 2025 | msn.comCytokinetics (NASDAQ:CYTK) Now Covered by Analysts at Raymond James FinancialAugust 1, 2025 | americanbankingnews.comRaymond James downgrades Cytokinetics (CYTK) to a HoldJuly 31, 2025 | theglobeandmail.comCytokinetics Merits A Speculative Buy RatingJuly 25, 2025 | seekingalpha.comSee More Headlines CYTK Stock Analysis - Frequently Asked Questions How have CYTK shares performed this year? Cytokinetics' stock was trading at $47.04 on January 1st, 2025. Since then, CYTK stock has decreased by 25.1% and is now trading at $35.25. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) posted its earnings results on Thursday, August, 7th. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.20. The firm's revenue was up 26727.3% on a year-over-year basis. Read the conference call transcript. Who are Cytokinetics' major shareholders? Cytokinetics' top institutional investors include Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. (0.91%), Aberdeen Group plc (0.77%), TD Asset Management Inc (0.46%) and E. Ohman J or Asset Management AB (0.34%). Insiders that own company stock include Robert I Blum, Fady Ibraham Malik, John T Henderson, Andrew Callos, Edward M Md Kaye, Wendall Wierenga, Muna Bhanji, B Lynne Parshall, Robert Wong and Robert Arthur Harrington. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and GE Aerospace (GE). Company Calendar Last Earnings5/06/2025Today8/07/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTK CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees250Year Founded1997Price Target and Rating Average Price Target for Cytokinetics$70.92 High Price Target$120.00 Low Price Target$41.00 Potential Upside/Downside+101.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($5.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$589.53 million Net Margins-3,201.47% Pretax Margin-3,201.47% Return on EquityN/A Return on Assets-43.75% Debt Debt-to-Equity RatioN/A Current Ratio5.99 Quick Ratio5.99 Sales & Book Value Annual Sales$19.22 million Price / Sales219.02 Cash FlowN/A Price / Cash FlowN/A Book Value($1.15) per share Price / Book-30.65Miscellaneous Outstanding Shares119,427,000Free Float116,202,000Market Cap$4.21 billion OptionableOptionable Beta0.64 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:CYTK) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.